Meeting
2024 ASCO Genitourinary Cancers Symposium
Factors predictive of primary resistance (PrimRes) to immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial cancer (mUC).
Authors
Nikhil Pramod
Cleveland Clinic Lerner College of Medicine, Cleveland, OH
Nikhil Pramod , Scott Dawsey , Ubenthira Patgunarajah , David Lynn , Wei Wei , Charbel Hobeika , Monica Nair , Allison Martin , Kimberly Maroli , Moshe Chaim Ornstein , Christopher Eing Wee , Timothy D. Gilligan , Amanda Nizam , Amanda Bonham , Omar Y. Mian , Paul G. Pavicic Jr., C. Marcela Diaz-Montero , Shilpa Gupta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Other
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 703)
DOI
10.1200/JCO.2024.42.4_suppl.703
Abstract #
703
Poster Bd #
M3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Effect of body mass index (BMI) on efficacy of immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: David Lynn
Poster
2021 Genitourinary Cancers Symposium
Impact of primary tumor location, histology, and host factors on objective response to immune checkpoint inhibitors in metastatic urothelial carcinoma.
First Author: Scott Dawsey
Poster
2024 ASCO Genitourinary Cancers Symposium
Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
First Author: Nikhil Pramod
Poster
2023 ASCO Genitourinary Cancers Symposium
US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval.
First Author: Haojie Li